Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
Diabetic kidney disease and its comorbid conditions, including atherosclerotic
cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions …
cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions …
Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial
F Persson, SC Bain, O Mosenzon… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE A post hoc analysis to investigate the association between 1-year changes in
albuminuria and subsequent risk of cardiovascular and renal events. RESEARCH DESIGN …
albuminuria and subsequent risk of cardiovascular and renal events. RESEARCH DESIGN …
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta …
Background Recent large clinical trials have demonstrated cardiovascular benefits of similar
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial
Importance Type 2 diabetes (T2D) is the leading cause of kidney disease in the US. It is not
known whether glucose-lowering medications differentially affect kidney function. Objective …
known whether glucose-lowering medications differentially affect kidney function. Objective …
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
BJ von Scholten, FF Kreiner… - Therapeutic …, 2022 - journals.sagepub.com
Chronic kidney disease (CKD) affects around 10% of the global population and is most often
caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive …
caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive …
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …
Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study
B Pasternak, V Wintzell, B Eliasson… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE To assess the association between use of glucagon-like peptide 1 (GLP-1)
receptor agonists and risk of serious renal events in routine clinical practice. RESEARCH …
receptor agonists and risk of serious renal events in routine clinical practice. RESEARCH …
[HTML][HTML] Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota: Gut-kidney axis in diabetic nephropathy
Y Ni, L Zheng, S Nan, L Ke, Z Fu… - Acta Biochimica et …, 2022 - ncbi.nlm.nih.gov
The role of gut-kidney crosstalk in the progression of diabetic nephropathy (DN) is receiving
increasing concern. On one hand, the decline in renal function increases circulating uremic …
increasing concern. On one hand, the decline in renal function increases circulating uremic …
Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk
JW Stephens, KE Brown, T Min - Diabetes, Obesity and …, 2020 - Wiley Online Library
This review examines the current literature relating to diabetes related kidney disease (DKD)
and the optimal management of cardio‐renal risk. DKD develops in approximately 40% of …
and the optimal management of cardio‐renal risk. DKD develops in approximately 40% of …
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased …
J Lin, SA Pearson, JR Greenfield, KH Park… - European Journal of …, 2023 - Springer
Purpose To investigate trends in SGLT2i and GLP-1RA use in Australia in the era of
increased evidence of their cardiovascular benefits. Methods We used national dispensing …
increased evidence of their cardiovascular benefits. Methods We used national dispensing …